tbuckley/cabot-search huggingface dataset:
Breast Milk–Acquired Cytomegalovirus in Premature Infants
Authors: Mark R. Schleiss
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling
Authors: Farhad Dastmalchi, Aida Karachi, Changlin Yang, Hassan Azari, Elias Joseph Sayour, Anjelika Dechkovskaia, Alexander Loren Vlasak, Megan Ellen Saia, Rolando Eladio Lovaton, Duane Anthony Mitchell, Maryam Rahman
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Dendritic cell (DC) vaccine efficacy is directly related to the efficiency of DC migration to the lymph node after delivery to the patient. We discovered that a naturally occurring metabolite, sarcosine, increases DC migration in human and murine cells resulting in significantly improved anti-tumor efficacy. We hypothesized that sarcosine induced cell migration was due to chemokine signaling. <h3>Methods</h3> DCs were harvested from the bone marrow of wild type C57BL/6 mice and electroporated with tumor messenger RNA (mRNA). Human DCs were isolated from peripheral blood mononuclear cells (PBMCs). DCs were treated with 20 mM of sarcosine. Antigen specific T cells were isolated from transgenic mice and injected intravenously into tumor bearing mice. DC vaccines were delivered via intradermal injection. In vivo migration was evaluated by flow cytometry and immunofluorescence microscopy. Gene expression in RNA was investigated in DCs via RT-PCR and Nanostring. <h3>Results</h3> Sarcosine significantly increased human and murine DC migration in vitro. In vivo sarcosine-treated DCs had significantly increased migration to both the lymph nodes and spleens after intradermal delivery in mice. Sarcosine-treated DC vaccines resulted in significantly improved tumor control in a B16F10-OVA tumor flank model and improved survival in an intracranial GL261-gp100 glioma model. Gene expression demonstrated an upregulation of CXCR2, CXCL3 and CXCL1 in sarcosine- treated DCs. Further metabolic analysis demonstrated the up-regulation of cyclooxygenase-1 and Pik3cg. Sarcosine induced migration was abrogated by adding the CXCR2 neutralizing antibody in both human and murine DCs. CXCR2 neutralizing antibody also removed the survival benefit of sarcosine-treated DCs in the tumor models. <h3>Conclusion</h3> Sarcosine increases the migration of murine and human DCs via the CXC chemokine pathway. This platform can be utilized to improve existing DC vaccine strategies.
The Night the Spirit Moved Uncle Elijah
Authors: Jude T. Okonkwo
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Authors: Javier Munoz, Samantha Jaglowski, Matthew S. McKinney, Iris Isufi, Patrick J. Stiff, Jessica Sachs, Ann Ranger, Patricia Harris, Francis Payumo, Luke P. Akard
Journal: Blood (2019)
Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Authors: K. Watanabe, A. Kohyama, H. Suzuki, T. Kajiwara, H. Karasawa, S. Ohnuma, H. Musha, T. Kamei, T. Naitoh, M. Unno
Journal: Annals of Oncology (2019)
US charity pays $4m to settle allegations it paid patients kickbacks from drug makers
Authors: Owen Dyer
Journal: BMJ (2019)

The Assistance Fund (TAF), a charity based in Orlando, Florida, will pay $4m (£3.1m; $3.6m) to settle claims that it served as a conduit for kickbacks from the drug manufacturers Teva, Biogen, and Novartis that aimed to encourage Medicare patients with multiple sclerosis to use their expensive products.

Medicare, the public insurance scheme for people aged 65 or over, covers most of a drug’s price, but patients must cover a small portion through a copayment. This is intended to introduce market forces by making more expensive drugs a costlier choice for patients as well as taxpayers.

The Anti-Kickback Statute, a federal law, bans drug manufacturers from covering copayments on patients’ behalf, as this could increase Medicare patients’ use of very expensive drugs, …
The complex challenges of HIV vaccine development require renewed and expanded global commitment
Authors: Linda-Gail Bekker, Roger Tatoud, Francois Dabis, Mark Feinberg, Pontiano Kaleebu, Mary Marovich, Thumbi Ndung'u, Nina Russell, Jeremiah Johnson, Maureen Luba, Anthony S Fauci, Lynn Morris, Giuseppe Pantaleo, Susan Buchbinder, Glenda Gray, Johan Vekemans, Jerome H Kim, Yves Levy, Lawrence Corey, Robin Shattock, Michael Makanga, Carolyn Williamson, Carl Dieffenbach, Maureen M Goodenow, Yiming Shao, Silvija Staprans, Mitchell Warren, Margaret I Johnston
Journal: The Lancet (2019)
Long noncoding RNA LCAT1 functions as a ceRNA to regulate RAC1 function by sponging miR-4715-5p in lung cancer
Authors: Juze Yang, Qiongzi Qiu, Xinyi Qian, Jiani Yi, Yiling Jiao, Mengqian Yu, Xufan Li, Jia Li, Chunyi Mi, Jisong Zhang, Bingjian Lu, Enguo Chen, Pengyuan Liu, Yan Lu
Journal: Molecular Cancer (2019)

Abstract Introduction Long noncoding RNAs (lncRNAs) are emerging as key players in the development and progression of cancer. However, the biological role and clinical significance of most lncRNAs in lung carcinogenesis remain unclear. In this study, we identified and explored the role of a novel lncRNA, lung cancer associated transcript 1 (LCAT1), in lung cancer. Methods We predicted and validated LCAT1 from RNA-sequencing (RNA-seq) data of lung cancer tissues. The LCAT1–miR-4715-5p–RAC1 axis was assessed by dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. Signaling pathways altered by LCAT1 knockdown were identified using RNA-seq. Furthermore, the mechanism of LCAT1 was investigated using loss-of-function and gain-of-function assays in vivo and in vitro. Results LCAT1 is an oncogene that is significantly upregulated in lung cancer tissues and associated with poor prognosis. LCAT1 knockdown caused growth arrest and cell invasion in lung cancer cells in vitro, and inhibited tumorigenesis and metastasis in the mouse xenografts. Mechanistically, LCAT1 functions as a competing endogenous RNA for miR-4715-5p, thereby leading to the upregulation of the activity of its endogenous target, Rac family small GTPase 1 (RAC1). Moreover, EHop-016, a small molecule inhibitor of RAC1, as an adjuvant could improve the Taxol monotherapy against lung cancer cells in vitro. Conclusions LCAT1–miR-4715-5p–RAC1/PAK1 axis plays an important role in the progression of lung cancer. Our findings may provide valuable drug targets for treating lung cancer. The novel combination therapy of Taxol and EHop-016 for lung cancer warrants further investigation, especially in lung cancer patients with high LCAT1 expression.
Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia
Authors: Junfang Yang, Pengfei Jiang, Xian Zhang, Xiaobin Zhu, Qi Dong, Jiaping He, Nanjing Lin, Zhenguang Wang, Songbai Cai, Xun Ye, Yunchao Su, Wenqian Li, Jingjing Li, Ziyao Yu, Jiujiang He, Li Xu, Dan Song, Wei Cao, Peihua Lu
Journal: Blood (2019)
Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
Authors: Mathias J Rummel, Christian Lerchenmüller, Manfred Hensel, Martin Goerner, Christian Buske, Holger Schulz, Burkhard Schmidt, Georgi Kojouharoff, Elisabeth Lange, Wolfgang Willenbacher, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, Axel Hinke, Jasmin Wupperfeld, Richard Greil
Journal: Blood (2019)
Life expectancy and disease burden in the Nordic countries: results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
Authors: Ann Kristin Knudsen, Peter Allebeck, Mette C Tollånes, Jens Christoffer Skogen, Kim Moesgaard Iburg, John J. McGrath, Knud Juel, Emilie Elisabet Agardh, Johan Ärnlöv, Tone Bjørge, Juan J Carrero, Christopher R. Cederroth, Anne Elise Eggen, Ziad El-Khatib, Christian Lycke Ellingsen, Seyed-Mohammad Fereshtehnejad, Mika Gissler, Kishor Hadkhale, Rasmus Havmoeller, Lars Johansson, Peter Benedikt Juliusson, Aliasghar A Kiadaliri, Sezer Kisa, Adnan Kisa, Tea Lallukka, Teferi Mekonnen, Tuomo J Meretoja, Atte Meretoja, Mohsen Naghavi, Subas Neupane, Truc Trung Nguyen, Max Petzold, Oleguer Plana-Ripoll, Rahman Shiri, Rannveig Sigurvinsdottir, Vegard Skirbekk, Søren T Skou, Inga Dora Sigfusdottir, Timothy J Steiner, Gerhard Sulo, Thomas Clement Truelsen, Tommi Juhani Vasankari, Elisabete Weiderpass, Stein Emil Vollset, Theo Vos, Simon Øverland
Journal: The Lancet Public Health (2019)

The Nordic countries have commonalities in gender equality, economy, welfare, and health care, but differ in culture and lifestyle, which might create country-wise health differences. This study compared life expectancy, disease burden, and risk factors in the Nordic region.
A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models
Authors: Jing Jin, Nina Xue, Yuan Liu, Rong Fu, Mingjin Wang, Ming Ji, Fangfang Lai, Jinping Hu, Xiaojian Wang, Qiong Xiao, Xiaoying Zhang, Dali Yin, Liping Bai, Xiaoguang Chen, Shuan Rao
Journal: Acta Pharmaceutica Sinica B (2019)

Psoriasis is characterized by abnormal proliferation of keratinocytes, as well as infiltration of immune cells into the dermis and epidermis, causing itchy, scaly and erythematous plaques of skin. The understanding of this chronic inflammatory skin disease remains unclear and all available treatments have their limitations currently. Here, we showed that IMMH002, a novel orally active S1P1 modulator, desensitized peripheral pathogenic lymphocytes to egress signal from secondary lymphoid organs and thymus. Using different psoriasis animal models, we demonstrated that IMMH002 could significantly relieve skin damage as revealed by PASI score and pathological injure evaluation. Mechanistically, IMMH002 regulated CD3+ T lymphocytes re-distribution by inducing lymphocytes' homing, thus decreased T lymphocytes allocation in the peripheral blood and skin but increased in the thymus. Our results suggest that the novel S1P1 agonist, IMMH002, exert extraordinary capacity to rapidly modulate T lymphocytes distribution, representing a promising drug candidate for psoriasis treatment.
Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial
Authors: David J Keene, Joseph Alsousou, Paul Harrison, Philippa Hulley, Susan Wagland, Scott R Parsons, Jacqueline Y Thompson, Heather M O’Connor, Michael Maia Schlüssel, Susan J Dutton, Sarah E Lamb, Keith Willett
Journal: BMJ (2019)

Abstract Objective To determine whether an injection of platelet rich plasma improves outcomes after acute Achilles tendon rupture. Design Randomised, placebo controlled, two arm, parallel group, participant and assessor masked, superiority trial. Setting Secondary care trauma units across 19 hospitals in the United Kingdom’s health service. Participants Recruitment commenced in July 2015 and follow-up was completed in March 2018. 230 adults aged 18 years and over were included, with acute Achilles tendon rupture presenting within 12 days of injury and managed with non-surgical treatment. Exclusions were injury at the insertion or musculotendinous junction, major leg injury or deformity, diabetes mellitus, platelet or haematological disorder, systemic corticosteroids, anticoagulation treatment, and other contraindicating conditions. Interventions Participants were randomised 1:1 to platelet rich plasma (n=114) or placebo (dry needle; n=116) injection. All participants received standard rehabilitation care (ankle immobilisation followed by physiotherapy). Main outcomes and measures Primary outcome was muscle tendon function at 24 weeks, measured objectively with the limb symmetry index (injured/uninjured×100) in maximal work done during the heel rise endurance test (an instrumented measure of repeated single leg heel rises until fatigue). Secondary outcomes included patient reported function (Achilles tendon rupture score), quality of life (short form 12 version 2®), pain (visual analogue scale), goal attainment (patient specific functional scale), and adverse events. A central laboratory analysed the quality and content of platelet rich plasma. Analyses were by modified intention to treat. Results Participants were 46 years old on average, and 57 (25%) of 230 were female. At 24 weeks, 202 (88%) participants completed the heel rise endurance test and 216 (94%) the patient reported outcomes. The platelet rich plasma was of good quality, with expected growth factor content. No difference was detected in muscle tendon function between participants receiving platelet rich plasma injections and those receiving placebo injections (limb symmetry index, mean 34.7% (standard deviation 17.7%) v 38.5% (22.8%); adjusted mean difference −3.9% (95% confidence interval −10.5% to 2.7%)) or in any secondary outcomes or adverse event rates. Complier average causal effect analyses gave similar findings. Conclusions There is no evidence to indicate that injections of platelet rich plasma can improve objective muscle tendon function, patient reported function, or quality of life after acute Achilles tendon rupture compared with placebo, or that they offer any patient benefit. Trial registration ISRCTN54992179.
Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors
Authors: Dyana T. Saenz, Warren Fiskus, Christopher P. Mill, Dimuthu Perera, Taghi Manshouri, Bernardo H. Lara, Vrajesh Karkhanis, Sunil Sharma, Stephen K. Horrigan, Prithviraj Bose, Tapan M. Kadia, Lucia Masarova, Courtney D. DiNardo, Gautam Borthakur, Joseph D. Khoury, Koichi Takahashi, Srividya Bhaskara, Charles Y. Lin, Michael R. Green, Cristian Coarfa, Craig M. Crews, Srdan Verstovsek, Kapil N. Bhalla
Journal: Blood (2020)
Post-Transplant Cyclophosphamide Improved Outcomes of HLA Mismatched Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major
Authors: Jianyun Wen, Yuelin He, Xiaoxiao Xu, Libai Chen, Xuedong Wu, Xiaoqin Feng, Chunfu Li, Xuan Liu, Fuyu Pei
Journal: Blood (2019)
A man with a traumatic lower limb injury
Authors: James Morris, Usman N Bhatty
Journal: BMJ (2019)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following A man with a traumatic lower limb injury Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Comparison of a combined MHC tetramer and interferon-γ (IFN-γ) intracellular cytokine staining (ICS) assay with individual MHC-tetramer and IFN-γ ELISPOT assays to monitor cancer immunotherapy
Authors: Begonya Comin-Anduix, Roberto Renteria, Jason Jalil, Pilar de la Rocha, Denise Oseguera, Jackie Hernandez, Arturo Villanueva, James Economou, John Gaspy, Antonio Gualberto, Antoni Ribas
Journal: Cancer Research (2007)

1866  Background: Validation of ex vivo immune monitoring methods is a high priority for the clinical development of novel cancer-immunotherapy strategies. We investigated whether the combination of IFN-γ ICS and tetramer assay resulted in an assay that combines the robustness and quantitative results of MHC tetramer and the functional information derived from IFN-γ enzyme-linked immunospot (ELISPOT) assays, resulting in a more efficient way to conduct immune-monitoring assays.  Methods: Eligible subjects were HLA-A*0201 with a baseline level of MART-126-35-, EBV-BMLF1- and/or CMVpp65-reactive CD8+ T cells above the tetramer assay’s low limit of detection (LLD) of 0.03%. Subjects received no intercurrent therapy. 100 ml of peripheral blood was collected twice separated by at least 15 days. Samples were cryopreserved and analyzed by iTAg MHC Tetramer IFN-γ kit from Beckman Coulter and compared to our standardized gold standard assays of MHC tetramer staining and IFN-γ ELISPOT (Comin-Anduix et al. Clin Ca Res 06). The Pearson coefficient with a 95% confident interval was computed to establish correlation between the assay results.  Results: 10 subjects (2 healthy donors and 8 melanoma patients) had EBV-BMLF1, 1 had MART-126-35 and 4 had CMV-pp65-specific cells above the tetramer LLD. Following the manufacturer’s instructions, the combined tetramer-IFN-γ ICS assay reproducibly overestimated the number of antigen-specific T cells by approximately 1 log compared to the results with the tetramer assay alone (mean EBV-BMLF1 tetramer 0.86vs. 5.68 by ICS-tetramer, paired t-test p   Conclusion: A modified tetramer-IFN-γ ICS assay can efficiently quantitate circulating antigen-specific T cells. Although results of the tetramer-IFN-γ ICS assay do not correlate with the functional IFN-γ ELISPOT assay, the addition of ICS to the tetramer assay provides specific functional phenothyping information on antigen-specific IFN-γ producing cells in peripheral blood.
I3: A Self-organising Learning Workflow for Intuitive Integrative Interpretation of Complex Genetic Data
Authors: Yun Tan, Lulu Jiang, Kankan Wang, Hai Fang
Journal: Genomics Proteomics & Bioinformatics (2019)

Abstract We propose a computational workflow (I3) for intuitive integrative interpretation of complex genetic data mainly building on the self-organising principle. We illustrate the use in interpreting genetics of gene expression and understanding genetic regulators of protein phenotypes, particularly in conjunction with information from human population genetics and/or evolutionary history of human genes. We reveal that loss-of-function intolerant genes tend to be depleted of tissue-sharing genetics of gene expression in brains, and if highly expressed, have broad effects on the protein phenotypes studied. We suggest that this workflow presents a general solution to the challenge of complex genetic data interpretation. I3 is available at http://suprahex.r-forge.r-project.org/I3.html.
Abstract 15407: Humanity in a Dish: Investigating a Common Genetic Basis for Human Metabolic Disease With Induced Pluripotent Stem Cells
Authors: Curtis R Warren, John F O’Sullivan, Max Friesen, Caroline E Becker, Xiaoling Zhang, Poching Liu, Yoshiyuki Wakabayashi, Jordan E Morningstar, Xu Shi, Jihoon Choi, Fang Xia, Derek T Peters, Mary H Florido, Alexander M Tsankov, Eilene Duberow, Lauren Comisar, Jennifer Shay, Xin Jiang, Alexander Meissner, Kiran Musunuru, Sekar Kathiresan, Laurence Daheron, Jun Zhu, Robert E Gerszten, Rahul Deo, Ramachandran S Vasan, Christopher J O’Donnell, Chad A Cowan
Journal: Circulation (2016)

Introduction: The NHLBI Framingham Heart Study (FHS) is a prospective community-based study focused on the epidemiology of myocardial infarction (MI) and other forms of cardiovascular disease. One ...
Could Tobacco Control Policies Be a Smokescreen?
Authors: Alain Braillon
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden
Authors: Theodoros Karantanos, Evan M Braunstein, Shruti Chaturvedi, Jerry L. Spivak, Linda Resar, Styliani Karanika, Donna Marie Williams, Christopher D Gocke, Alison R. Moliterno
Journal: Blood (2019)